Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 51, Issue 7, 2010, Pages 1233-1240

  Shanafelt, Tait D ^a   Rabe, Kari G ^a   Kay, Neil E ^a   Zent, Clive S ^a   Call, Timothy G ^a   Slager, Susan L ^a   Bowen, Deborah A ^a   Schwager, Susan M ^a   Nowakowski, Grzegorz S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chronic lymphocytic leukemia; medications; neoplasia; non Hodgkin lymphoma; non steroidal anti inflammatory drugs; statins

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; MEVINOLIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; RITUXIMAB; ROSUVASTATIN; SIMVASTATIN;

AGED; ARTICLE; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFECT; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SALVAGE THERAPY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; NEOPLASM STAGING; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77954097693     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.486877     Document Type: Article

References (41)

1. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002;287:337-344.
2. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 2008;42:1208-1215.
3. Solomon D. Nonselective NSAIDs: overview of adverse effects. 2009. Available from: http://www.uptodate.com.
4. Endo A. The discovery and development of HMG-CoA reductase inhibitors. 1992. Atheroscler Suppl 2004;5:67-80.
5. Jakobisiak M, Golab J. Potential antitumor effects of statins (Review). Int J Oncol 2003;23:1055-1069.
6. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005;115:959-968.
7. Perez-Sala D, Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem Biophys Res Commun 1994;199:1209-1215.
8. Mausner-Fainberg K, Luboshits G, Mor A, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008;197:829-839.
9. Schramm R, Menger MD, Harder Y, et al. Statins inhibit lymphocyte homing to peripheral lymph nodes. Immunology 2007;120:315-324.
10. Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H, Lishner M. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol 2003;31:779-783.
11. Vitols S, Angelin B, Juliusson G. Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans-in vitro and in vivo studies. Lipids 1997;32: 255-262.
12. Madden EA, Melnykovych G, Fiskin AM. Compactin (ML- 236B) reduces the content of filipin-cholesterol complexes in the plasma membrane of chronic lymphocytic leukemia cells. Exp Cell Res 1984;153:91-98.
13. Weinberg JB, Volkheimer AD, Mihovilovic M, et al. Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia. Leukemia 2008;22:2184-2192.
14. Oppezzo P, Vasconcelos Y, Settegrana C, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005;106: 650-657.
15. Nuckel H, Huttmann A, Klein-Hitpass L, et al. Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2006;47:1053-1061.
16. Heintel D, Kienle D, Shehata M, et al. High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia 2005;19:1216-1223.
17. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet 2009;373:1301-1309.
18. Ryan EP, Pollock SJ, Kaur K, et al. Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells. Clin Immunol 2006;120:76-90.
19. Bellosillo B, Pique M, Barragan M, et al. Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood 1998;92:1406-1414.
20. Ryan EP, Bushnell TP, Friedman AE, Rahman I, Phipps RP. Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells. Cancer Immunol Immunother 2008;57:347-358.
21. Robak P, Linke A, Cebula B, Robak T, Smolewski P. Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo Bcell chronic lymphocytic leukemia cells. Leuk Lymphoma 2006;47:2625-2634. (Pubitemid 44932654)
22. Lindhagen E, Nissle S, Leoni L, et al. R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX- 309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells. Cancer Chemother Pharmacol 2007;60:545-553.
23. Winiarska M, Bil J, Wilczek E, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med 2008;5:e64.
24. Hallek M. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 2008;112(Suppl. 1): (Abstract 325).
25. Hallek M, Fingerle-Rowson G, Fink A, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituixmab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood 2009;114(Suppl. 1): (Abstract 535).
26. Robak T, Moiseev SI, Dmoszynska A, et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized phase III REACH Trial. Blood 2008;112(Suppl. 1): (Abstract 1).
27. Rabinowitz I. Interaction between statins and rituximab in non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5486; author reply 5486.
28. Goldstein MR, Mascitelli L, Pezzetta F. Monoclonal antibody therapy and non-Hodgkin's lymphoma. N Engl J Med 2009;360:192; author reply 193.
29. Nowakowski GS, Maurer MJ, Habermann TM, et al. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol 2010;28:412-417.
30. Shanafelt TD, Jelinek D, Tschumper R, et al. Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemia. J Clin Oncol 2006;24:3218-3219.
31. Zent CS, Ding W, Schwager SM, et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/ small lymphocytic lymphoma. Br J Haematol 2008;141:615-621.
32. Maddocks-Christianson K, Slager SL, Zent CS, et al. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol 2007;139:398-404.
33. Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008;49:49-56.
34. Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolonerituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007;48: 2412-2417.
35. Palmer S, Hanson CA, Zent CS, et al. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol 2008;141:607-614.
36. Dewald G, Brockman S, Paternoster S, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of chronic lymphocytic leukemia. Br J Haematol 2003;121:287-295.
37. Jelinek DF, Tschumper RC, Geyer SM, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001;115:854-861.
38. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006;24:4634-4641.
39. Friedman DR, Harrison JD, Magura LA, Warren HA, Diehl LF, Weinberg JB. Influence of statin therapy on the clinical course of chronic lymphocytic leukemia. Blood 2009; 114(Suppl. 1): (Abstract 2344).
40. Jensen M, Engert A, Weissinger F, et al. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. Invest New Drugs 2008;26: 139-149.
41. Moon EY, Lerner A. Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells. Cancer Res 2002;62:5711-5719.